Our results highlight that a corresponding circulating PIK3CA mutation was identified in 55% of non-metastatic IBC patients with a baseline somatic PIK3CA mutation in tumour tissue and with detectable cfDNA, while no circulating mutation was found among patients with no PIK3CA mutations. Here, PIK3CA is linked to neoplasm.